MedTrace Logo

HypErsensitiVity PneumonITis: DiseAse Progression Characterization

NCT04961944 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-06-29

No results posted yet for this study

Summary

EVITA is a multicentric Latin-American prospective cohort on chronic hypersensitivity pneumonitis. EVITA's objective is to identify phenotypes and/or endotypes associated with different disease trajectories measured primarily by forced vital capacity (FVC) during a 24 month follow-up period. Other secondary measures of disease progression will also be investigated such as imaging, time to death or lung transplantation, and patient-reported outcomes

Conditions

  • Hypersensitivity Pneumonitis

Interventions

OTHER

Disease assessment

A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed. The association between endotypes and disease progression will be tested.

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Centro Rossi, Buenos Aires, Argentina

    collaborator UNKNOWN

  • Hospital do Coracao

    lead OTHER

Principal Investigators

  • Leticia Kawano Dourado, MD · HCOR Research Institute, Hospital do Coracao, São Paulo, Brazil

  • Prof. Alexandra Latini, PhD · Federal University of Santa Catarina

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-20
Primary Completion
2025-12-01
Completion
2026-03-01

Countries

  • Argentina
  • Brazil
  • Chile

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04961944 on ClinicalTrials.gov